Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Bio-Rad Laboratories A / Equity Bottom-Up

<ul><li>Bio-Rad, in its second quarter of 2024, presents a mix of performances and outlook corrections amidst a complex operating environment.</li><li>CEO Norman Schwartz highlighted that the quarter saw revenue meeting expectations and a better-than-expected margin performance due to favorable product mix and good cost management.</li><li>Despite these positives, the company is facing challenges specifically within the biotech and biopharma sectors, leading to a cautious revision of its full-year 2024 financial outlook.</li></ul>

Bio-Rad, in its second quarter of 2024, presents a mix of performances and outlook corrections amidst a complex operating environment.CEO Norman Schwartz highlighted that the quarter saw revenue meeting expectations and a better-than-expected margin performance due to favorable product mix and good cost management.Despite these positives, the company is facing challenges specifically within the biotech and biopharma sectors, leading to a cautious revision of its full-year 2024 financial outlook.

Bio-Rad Laboratories: A Strengthened Position in Digital PCR (ddPCR) and Diagnostics With Solid Presence In China! - Major Drivers

<ul><li>Bio-Rad Laboratories, a multinational firm delivering scientific research products and clinical diagnostics, reported its first-quarter 2024 financial results performing as per their internal estimates.</li><li>The primary factor for their performance fluctuations was the macroeconomic and market trends due to the biotech and biopharma segments in countries such as China and Russia.</li><li>The company observed a decline in the Life Science Group, albeit in line with their expectations.</li></ul>

Bio-Rad Laboratories, a multinational firm delivering scientific research products and clinical diagnostics, reported its first-quarter 2024 financial results performing as per their internal estimates.The primary factor for their performance fluctuations was the macroeconomic and market trends due to the biotech and biopharma segments in countries such as China and Russia.The company observed a decline in the Life Science Group, albeit in line with their expectations.

Bio-Rad Laboratories Inc.: Exciting New Product Launches Can Propel Their Revenue Growth? - Major Drivers

<ul><li>This is our first report on life science research and clinical diagnostic products manufacturer, Bio- Rad Laboratories.</li><li>The company's results exhibit resilience with substantial room for improvements and growth in the coming years.</li><li>Bio-Rad's FY 2023 net sales of $2.671 billion reflect a decrease by 4.7% on a reported basis as compared to 2022.</li></ul>

This is our first report on life science research and clinical diagnostic products manufacturer, Bio- Rad Laboratories.The company's results exhibit resilience with substantial room for improvements and growth in the coming years.Bio-Rad's FY 2023 net sales of $2.671 billion reflect a decrease by 4.7% on a reported basis as compared to 2022.

Bio Rad Laboratories: Initiation of Coverage - Unveiling the Future - Next-Gen Products That Will Skyrocket Your Portfolio! - Major Drivers

<ul><li>This is our first report on clinical diagnostic products manufacturer, Bio-Rad Laboratories.</li><li>The company's financial results for the third quarter of 2023 show varying performances across segments.</li><li>The call highlighted key issues including the impacts of Bio-pharma and the challenges in the economic conditions in China on the company's performances.</li></ul>

This is our first report on clinical diagnostic products manufacturer, Bio-Rad Laboratories.The company's financial results for the third quarter of 2023 show varying performances across segments.The call highlighted key issues including the impacts of Bio-pharma and the challenges in the economic conditions in China on the company's performances.

Bio-Rad Laboratories: Initiation of Coverage - How China's New Policies and a Global Recession Are Rocking Its Market! - Major Drivers

Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>Last Friday, the S&amp;P Index Committee announced the changes to the S&amp;P500, S&amp;P400, S&amp;P600, and other indices, along with the result of a recent consultation on capping methodology.</li>
<li>The result is about US$23bn a side of flows for the major indices</li>
<li>In the S&amp;P500, DELL, PLTR, and ERIE are ADDs. AAL, ETSY, and BIO are DELETEs. But as always, just knowing the names is deceptive. The history matters more.</li>
</ul>


Last Friday, the S&amp;P Index Committee announced the changes to the S&amp;P500, S&amp;P400, S&amp;P600, and other indices, along with the result of a recent consultation on capping methodology.
The result is about US$23bn a side of flows for the major indices
In the S&amp;P500, DELL, PLTR, and ERIE are ADDs. AAL, ETSY, and BIO are DELETEs. But as always, just knowing the names is deceptive. The history matters more.


S&P 500/400/600 Changes - DELL, PLTR, and ERIE Added, AAL, ETSY, BIO Deleted

United States

Bio-Rad Laboratories, Inc. is a multinational manufacturer and distributor of life science research products, clinical diagnostics, and analytical instrumentation.  The Company's products and systems separate complex chemical and biological materials, as well as identify, analyze, and purify their components.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Bio-Rad Laboratories A (BIO US)

Bio-Rad Laboratories: A Strengthened Position in Digital PCR (ddPCR) and Diagnostics With Solid Presence In China! - Major Drivers

Bio-Rad, in its second quarter of 2024, presents a mix of performances and outlook corrections amidst a complex operating environment. CEO Norman...

Baptista Research

Bio-Rad Laboratories Inc.: Exciting New Product Launches Can Propel Their Revenue Growth? - Major Drivers

Bio-Rad Laboratories, a multinational firm delivering scientific research products and clinical diagnostics, reported its first-quarter 2024...

Baptista Research

Bio Rad Laboratories: Initiation of Coverage - Unveiling the Future - Next-Gen Products That Will Skyrocket Your Portfolio! - Major Drivers

This is our first report on life science research and clinical diagnostic products manufacturer, Bio- Rad Laboratories. The company's results...

Baptista Research

Bio-Rad Laboratories: Initiation of Coverage - How China's New Policies and a Global Recession Are Rocking Its Market! - Major Drivers

This is our first report on clinical diagnostic products manufacturer, Bio-Rad Laboratories. The company's financial results for the third quarter...

Baptista Research

S&P 500/400/600 Changes - DELL, PLTR, and ERIE Added, AAL, ETSY, BIO Deleted

The S and P Index Committee announced its September changes to the major indices on Friday along with changes to the Sector indices which means...

Travis Lundy

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)